BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• Business

  Tonix Pharmaceuticals Announces New Board Member, R. Newcomb Stillwell

  Tonix Pharmaceuticals Holding Corp. today announced the appointment of R. Newcomb Stillwell to its Board of Directors, to be effective as of March 15, 2023.

  February 23, 2023

   · 

  5 min read
• Business

  Inogen Announces Fourth Quarter and Full Year 2022 Financial Results

  Inogen, Inc today announced financial results for the fourth quarter and the full year ended December 31, 2022.

  February 23, 2023

   · 

  17 min read
• AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023

  AbCellera (Nasdaq: ABCL) today announced that it will present at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023, at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

  February 23, 2023

   · 

  1 min read
• Pharm Country

  Olatec Therapeutics Announces the Final Closing, Led by Sanders Morris Harris, on Its $40 Million Series A Financing Round

  Olatec Therapeutics LLC (“ Olatec ” or the “ Company ”), a leader in developing NLRP3 inhibitors, announced the completion of the Company’s $40 million Series A round financing, the final closing of which was led by Sanders Morris Harris (“ SMH ”).

  February 23, 2023

   · 

  7 min read
• Business

  Generation Bio Outlines 2023 Strategic Priorities and Reports Fourth Quarter and Full Year 2022 Financial Results

  Generation Bio Co outlined its strategic priorities for 2023 and reported fourth quarter and full year 2022 financial results.

  February 23, 2023

   · 

  7 min read
• Drug Development

  Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus

  Nektar Therapeutics (Nasdaq: NKTR) today announced topline data from a Phase 2 randomized, double-blind, placebo-controlled study of rezpegaldesleukin.

  February 23, 2023

   · 

  10 min read
• Business

  Apollo Medical Holdings, Inc. Reports Fourth Quarter and Year-End 2022 Results

  Apollo Medical Holdings, Inc. today announced its consolidated financial results for the fourth quarter and year ended December 31, 2022.

  February 23, 2023

   · 

  20 min read
• Business

  Select Medical Holdings Corporation Announces Results For Its Fourth Quarter and Year Ended December 31, 2022 and Cash Dividend

  Select Medical Holdings Corporation announced results for its fourth quarter and year ended December 31, 2022 and the declaration of a cash dividend.

  February 23, 2023

   · 

  36 min read
• Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901

  Keymed Biosciences Inc., and Lepu Biopharma Co., Ltd, jointly announce a global exclusive licence agreement with AstraZeneca for CMG901, a potential first-in-class Claudin 18.2 antibody drug conjugate.

  February 23, 2023

   · 

  3 min read
• Business

  argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023

  argenx announced that it will host a conference call and audio webcast on Thursday, March 2, 2023 at 2:30 pm CET to discuss its full year 2022 financial results and provide a fourth quarter business update.

  February 23, 2023

   · 

  1 min read